Drug or technology
5 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
FDA approval of sugammadex sodium for intravenous use; this is a regulatory action, not a clinical efficacy study, and does not report trial outcomes or comparative benefit.
FDA approval of sugammadex sodium for intravenous use; this is a regulatory action record that does not contain clinical trial outcome data.
FDA approval of a generic sugammadex formulation; regulatory action does not provide clinical trial evidence of efficacy or comparative benefit.
FDA approval of a generic sugammadex formulation; this is a regulatory action record without clinical trial data.
FDA approval of a generic sugammadex formulation; regulatory action does not itself establish clinical efficacy or comparative benefit.